Medtronic (NYSE:MDT) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Medtronic (NYSE:MDT) released its quarterly earnings results on Tuesday. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02, FiscalAI reports. The company had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm’s revenue was up 5.8% compared to the same quarter last year. During the same period last year, the business posted $1.38 earnings per share. Medtronic updated its FY 2026 guidance to 5.620-5.660 EPS.

Medtronic Stock Performance

NYSE MDT opened at $99.57 on Tuesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The stock’s 50 day simple moving average is $99.25 and its 200-day simple moving average is $96.53. The company has a market cap of $127.65 billion, a PE ratio of 26.84, a price-to-earnings-growth ratio of 2.62 and a beta of 0.71. Medtronic has a 1-year low of $79.55 and a 1-year high of $106.33.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s dividend payout ratio is presently 76.55%.

Analyst Upgrades and Downgrades

MDT has been the subject of several research reports. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Royal Bank Of Canada lifted their price target on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Citigroup initiated coverage on Medtronic in a report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 target price for the company. Finally, Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Sixteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $111.21.

Hedge Funds Weigh In On Medtronic

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Blair William & Co. IL lifted its position in Medtronic by 7.0% during the fourth quarter. Blair William & Co. IL now owns 84,354 shares of the medical technology company’s stock worth $8,103,000 after buying an additional 5,499 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Medtronic in the fourth quarter valued at about $481,000. Opal Capital LLC acquired a new stake in Medtronic during the fourth quarter worth about $319,000. Rothschild Wealth LLC purchased a new position in Medtronic during the fourth quarter worth about $566,000. Finally, 71 West Capital Partners acquired a new stake in shares of Medtronic during the 4th quarter worth approximately $263,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 results beat expectations — non‑GAAP EPS $1.36 vs. $1.33 expected and revenue $9.02B vs. $8.89B consensus; management provided slides and a press release highlighting the outperformance. Press Release
• Positive Sentiment: Robust demand for cardiac devices and diabetes monitors helped drive the beat — analysts note strength in heart devices and ablation portfolio expansion as durable revenue drivers. Reuters: Demand Drive
• Positive Sentiment: Product and regulatory wins: FDA clearances (Hugo™ robotic system, Stealth AXiS™) plus CE mark and U.S. pivotal trial starts for other platforms; first U.S. Hugo commercial case reported — these expand addressable markets and support future growth. PR Newswire: Q3 Highlights
• Neutral Sentiment: FY2026 EPS guidance set to $5.620–5.660, which essentially aligns with the consensus (~$5.64) — guidance is not a material beat or miss, so it’s unlikely to sharply change expectations.
• Neutral Sentiment: Analyst commentary and previews are focusing on capital allocation and margin trajectory as investors digest results; these narratives may influence sentiment but not immediate fundamentals. Kalkine Media Benzinga Preview
• Negative Sentiment: Profit fell on a GAAP basis as costs and investments rose — higher spending to support growth and new product rollouts weighed on margins, a concern for investors focused on near‑term profitability. WSJ: Profit Falls
• Negative Sentiment: Antitrust/regulatory risk flagged in recent coverage — potential headwind if competitive or regulatory actions slow adoption of new surgical/spine products. Yahoo Finance: Antitrust

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).